Business
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antib
About this update from Tiziana Life Sciences Ltd
[{"type":"image","alt":"Tiziana Life Sciences Ltd.","displaySize":"","headline":null,"caption":"Tiziana Life Sciences Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k64r3yQgq2ENSiAhwIMCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947","width":264,"height":60}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid Therapies","length":117,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":210,"olType":false},{"type":"text","content":"BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that the first patient has been dosed with intranasal foralumab in its Phase 2 randomized, placebo-controlled clinical trial in patients with early Alzheimer’s disease (AD). This milestone follows the Company’s December 12, 2025 announcement that enrolment had begun and the first patient was expected to be dosed imminently. The Phase 2 trial evaluates intranasal foralumab both as monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab (Leqembi®) or donanemab, in patients with early AD.","length":821,"tagName":"p"},{"type":"text","content":"The trial is supported by TSPO-PET imaging data demonstrating persistent and widespread microglial activation—a hallmark of neuroinflammation—in Alzheimer’s patients, even after amyloid plaque reduction with lecanemab. This evidence underscores the need for therapies targeting residual neuroinflammation, which intranasal foralumab is designed to address by modulating immune responses and calming activated microglia.","length":419,"tagName":"p"},{"type":"text","content":"Gabriele Cerrone, Chairman & Founder of Ti...